(
out of
184
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Research North
Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City
,
UT
84112
Specialties
Board Certification
|
American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
American Board of Internal Medicine (Internal Medicine)
|
Patient Rating
5.0
/5
( out of
184 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Assistant Professor (Clinical) |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
American Board of Internal Medicine (Internal Medicine)
|
Education history
| Professional Medical | Medicine, Surgery - Aga Khan University, Medical College | M.B.B.S. |
|---|---|---|
| Residency | Internal Medicine Categorical Residency - University of Kansas Medical Center | Resident |
| Chief Resident | Internal Medicine - University of Kansas Medical Center | Chief Resident |
| Fellowship | Hematology-Oncology - University of Kansas Medical Center | Fellow |
Selected Publications
Journal Article
- Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2018). Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. Acta Haematol, 139(1), 52-57.
- Mohyuddin GR, Uy J, Medhavi H, Faisal MS, Qazilbash MH (2017). Immune-Mediated Neuropathies following Autologous Stem Cell Transplantation for Multiple Myeloma: Case Series and Review of the Literature. Acta Haematol, 137(2), 86-88.
- Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of endpoints in multiple myeloma randomized controlled trials over the last 15¿years: A systematic review. Am J Hematol, 96(6), 690-697.
- Mohyuddin GR, Dominick A, Black T, Hoffman M, Male H, Byrd K, McClune B, Eck L, Neupane P (2020). A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency.(Epub ahead of print). J Cancer Educ.
- Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, Ganguly S, McGuirk J, Kambhampati S (2021). Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 62(6), 1386-1395.
- Mohyuddin GR, Al Asad M, Scratchko L, Khaleeq G (2013). Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome. Am J Crit Care, 22(3), 270-3.
- Mohyuddin GR, Abbasi S, Okoniewski M, McClune B, Abdallah AO, Ganguly S, McGuirk J, Shune L (2020). Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation. Eur J Haematol, 105(5), 571-577.
- Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020). Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol, 104(5), 420-426.
- Pennipede D, Mohyuddin GR, Hawkins R, Ganguly S, Shune L, Ahmed N, Mohan M, Cui W, Mahmoudjafari Z, McGuirk J, Atrash S, Abdallah AO (2021). Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM).(Epub ahead of print). Eur J Haematol.
- Ferguson JE, Vetos D, Ho BV, Aziz M, Lee WM, Mohyuddin GR, Prouty M (2021). Trends in diversity of participants in dermatology clinical trials over time: A systematic review.(Epub ahead of print). J Am Acad Dermatol.
- Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res, 95, 106402.
- Britt A, Mohyuddin GR, Al-Rajabi R (2020). Maintenance of Stable Disease in Metastatic Perivascular Epithelioid Cell Tumor of the Liver With Single-Agent Sorafenib.(Epub ahead of print). Am J Ther.
- Dominick A, Mohyuddin GR, Fields-Meehan J, Mathur (2020). Combination Immunotherapy Associated With Severe Hepatotoxicity and Fatal Aplastic Anemia. American journal of therapeutics,
- Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi (2020). Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC cancer, 20(1), 507.
- Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin G (2021). Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC cancer, 21(1), 730.
- Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin G (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC cancer, 21(1), 339.
- Mohyuddin GR, Alam Z, Malik UZ, Shakil O, ul Haq (2015). REVISED TRAUMA SCORE AS A PREDICTOR OF OUTCOME IN TRAUMA CASES: EXPERIENCES AT A TERTIARY CARE HOSPITAL IN KARACHI, PAKISTAN. Journal of Ayub Medical College, Abbottabad, 27(3), 584-6.
- Parkash O, Mohyuddin GR, Ayub A, Nazir I, Maan AA, Hamid (2016). Electrophysiological changes in patients with liver cirrhosis in a tertiary care hospital in Karachi, Pakistan. Journal of Ayub Medical College, Abbottabad, 28(4), 676-679.
- Mohyuddin GR, Romanelli N, Shune L, Abhyankar S, Ganguly S, McGuirk J, Singh (2019). Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients. Hematology/oncology and stem cell therapy, 12(2), 124-125.
- Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh (2018). Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. Hematology/oncology and stem cell therapy, 11(3), 135-141.
- Abdallah AO, Sigle M, Mohyuddin GR, Coggins E, Remker C, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly (2021). Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 21(2), e220-e226.
- Abdallah AO, Mohyuddin GR, Mahmoudjafari Z, Atrash S, Kawsar H, Sigle M, Shune L, McGuirk J, Ganguly (2021). Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 21(2), e212-e219.
- Mohyuddin GR, Hampton J, Aziz M, Khuder S, Malik S, McClune B, Abdallah A (2021). A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 21(7), 489-496.
- Gaudel P, Mohyuddin GR, Fields-Meehan (2021). Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. Federal practitioner, 38(2), 89-91.
- Mohyuddin GR, Jobe A, Thomas (2020). Does Use of High-fidelity Simulation Improve Resident Physician Competency and Comfort Identifying and Managing Bradyarrhythmias?. Cureus, 12(2), e6872.
- Al-Kofahi M, Mohyuddin GR, Taylor ME, Eck L (2019). Reducing Resident Physician Workload to Improve Well Being. Cureus, 11(6), e5039.
- Mohyuddin GR, Isom N, Thomas (2019). Applying the Principles of Bloom's Taxonomy to Managing Tachyarrhythmia: Results of a Tachyarrhythmia Workshop. Cureus, 11(2), e4037.
- Mohyuddin GR, Lester K, Thomas L, Eck LM, Newman J (2021). Implementation of an Audience Response System in a Case Conference Curriculum: Results of a Placebo-Controlled Trial. Cureus, 13(2), e13512.
- Mohyuddin GR, Koehn K, Costa L, Kumar SK, McClune (2020). Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. The Lancet. Haematology, 7(10), e704-e706.
- Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad (2021). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. The Lancet. Haematology, 8(4), e299-e304.
- Mohyuddin GR, Abdallah AO, McClune (2021). Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma. JAMA oncology, 7(4), 635.
- Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar S (2021). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood advances, 5(4), 1097-1101.
- Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad (2021). Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA network open, 4(4), e218084.
- Mohyuddin GR, Qazilbash (2018). The role of NK Cells in Multiple Myeloma.
- Khan C, Mohyuddin G (2013). Bone Marrow Biopsy Simulation Training for Fellows. 4(4),
- Mohyuddin GR, Qureshi (2012). Recommendation for use of Vitamin ‘D’ Treatment during Pregnancy. 4, 223-6.
- Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy .Crit Rev Oncol Hematol. 2021 Aug 27:103453. doi: 10.1016/j.critrevonc.2021.103453. Online ahead of print.PMID: 34461271 Review. Online prior to print. (2021.103453),
- Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. 156(October 2021), 164-174.
- Mohyuddin GR, Mehra N, Ryll B, Prasad (2022). Control participants of randomised trials: an often forgotten, vulnerable population. The Lancet. Haematology, 9(9), e634-e636.
- McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin G (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. European journal of haematology, 109(5), 559-565.
- Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin G (2022). Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO global oncology, 8, e2200119.
- Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin G (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical hematology international, 4(1-2), 56-59.
- Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin G (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European journal of cancer (Oxford, England, 167, 152-160.
- Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin G (2022). Financial toxicity in hematological malignancies: a systematic review. Blood cancer journal, 12(4), 74.
- Berger K, Mohyuddin G (2022). Reporting of trials with possible detrimental overall survival: a patient advocate perspective. The Lancet. Haematology, 9(2), e94.
- Mohyuddin GR, Mian (2022). Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nature reviews. Clinical oncology, 19(1), 3-4.
- Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. European journal of cancer (Oxford, England, 156, 164-174.
- Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin G (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology, 200(5), 587-594.
- Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Hajjar S, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah A (2022). Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 22(12), 912-919.
- Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov D (2023). Impact of academic medical center access on outcomes in multiple myeloma. American journal of hematology, 98(1), 41-48.
- Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov (2022). A survey on the patient perspective on cure in multiple myeloma. The Lancet. Haematology, 9(10), e716-e719.
- Mohyuddin GR,Sinnarajah A,Gayowsky A,Chan KKW,Seow H,Mian (2022). Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada. British journal of haematology, 199(5), 688-695.
- Mohyuddin GR,Rabinowitz (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: Correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7(1),
- Sawalha L,Kelkar AH,Mohyuddin GR,Goodman AM,Gagelmann N,Al Hadidi (2023). Analysis of repeated roles in editorial boards at oncology focused journals. Journal of cancer policy, 35,
- Mohyuddin GR,Chakraborty R,Scheffer Cliff E (2023). The promise and harms of screening for plasma cell dyscrasias. British journal of haematology,
- Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin G (2023). Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. Journal of cancer policy, 36, 100411.
- Abdallah AO, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash (2023). Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. European journal of haematology, 110(6), 626-632.
- Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin G (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma, 64(7), 1-4.
- Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clinical hematology international, 5(2-3), 170-176.
- Mian A,Naqvi SAA,Ayaz A,Husnain M,Aljama MA,Mohyuddin GR,Koehn K,Mohan M,Bin Riaz I,Chakraborty (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leukemia research, 131,
- Sengar M,Hopman WM,Mohyuddin GR,Goodman AM,Gyawali B,Mukherji D,Hammad N,Pramesh CS,Aggarwal A,Sullivan R,Booth C (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17,
- Mohyuddin GR,Meirson (2023). A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise. Nature reviews. Clinical oncology,
- Booth CM,Sengar M,Goodman A,Wilson B,Aggarwal A,Berry S,Collingridge D,Denburg A,Eisenhauer EA,Ginsburg O,Goldstein D,Gunasekera S,Hammad N,Honda K,Jackson C,Karikios D,Knopf K,Koven R,Marini BL,Maskens D,Moraes FY,Mohyuddin GR,Poudyal BS,Pramesh CS,Roitberg F,Rubagumya F,Schott S,Sirohi B,Soto-Perez-de-Celis E,Sullivan R,Tannock IF,Trapani D,Tregear M,van der Graaf W,Vanderpuye V,Gyawali (2023). Common Sense Oncology: outcomes that matter. The Lancet. Oncology, 24(8), 833-835.
- Hentzen S,Meirson T,Koehn K,Goodman A,Chakraborty R,Sborov D,Rubinstein S,Mohyuddin G (2023). Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. European journal of haematology, 111(3), 491-498.
- Mohyuddin GR,Prasad (2023). Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast. JAMA internal medicine, 183(9), 897-898.
- Cliff ERS, Mohyuddin G (2022). Overall survival as a primary end point in multiple myeloma trials. Nature reviews. Clinical oncology, 19(9), 565-566.
- Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth C (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17, 1558.
- Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leukemia research, 131, 107324.
- Abdallah AO, Mohyuddin GR, Ahmed N, Mohan M, Cui W, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S, Atrash (2021). Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. EJHaem, 2(4), 757-764.
- McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, D'Souza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian (2023). Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica,
- Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Ng Liet Hing M, Harrison SJ, Kesselheim A, Teh B (2023). Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood advances,
- Balaban N, Mohyuddin GR, Kashi A, Massarweh A, Markel G, Bomze D, Goldstein DA, Meirson (2023). Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.), 383, e077329.
- Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi (2023). Use of subjective minimizing language at hematology and oncology conferences: A systematic review. Journal of cancer policy, 39, 100461.
- Mohyuddin GR, Chakraborty R, Cliff ERS, Derman B (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65, 102272.
- Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin G (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA network open, 6(11), e2342195.
- Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi (2023). Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI cancer spectrum, 7(6),
- Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin G (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood cancer journal, 14(1), 20.
- Mian H, Seow H, Pond GR, Gayowsky A, Foley R, Balistky A, Ebraheem M, Cipkar C, Sapru H, Mohyuddin GR, Hadidi SA, Visram (2024). Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical lymphoma, myeloma & leukemia,
- Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, Booth CM, Rd EH, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin G (2024). Dietary interventions in cancer: a systematic review of all randomized controlled trials. Journal of the National Cancer Institute,
- Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, Lentzsch S, Chakraborty (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3), e61.
- Mohyuddin GR, Goodman A (2024). Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials. Nature reviews. Clinical oncology,
- Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leukemia & lymphoma, 65(9), 1-4.
- Mohyuddin GR, Guadamuz JS, Ascha MS, Chiu BC, Patel PR, Sweiss K, Rohrer R, Sborov D, Calip G (2024). Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study. Blood advances, 8(21), 5539-5541.
- Kapur R, McCarron J, Rajeeve S, Mohyuddin G (2024). The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?. Leukemia & lymphoma, 1-3.
- Zhukovsky S, Cliff ERS, Mohyuddin G (2024). Should we screen for plasma cell dyscrasias in people with low bone density?. The Lancet. Haematology, 11(10), e715-e717.
- Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin G (2024). Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. The oncologist,
- Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, Sandhu I, McCurdy A, Facon T, Mateos MV, Mian (2024). Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood advances, 8(23), 5993-6002.
- Mohyuddin GR, Almasri J, Goodman A, Haslam A, Prasad (2024). The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma. The oncologist,
- Eisenhauer EA, Abdihamid O, Booth CM, Cherny N, Fojo AT, Gyawali B, Marini BL, Mohyuddin GR, Pe M, Pond GR, Soto-Perez-de-Celis E, Tannock IF, Trapani D, Tregear M, van der Graaf WTA, Wilson B (2025). Guidance for discussants of randomized cancer trials at major meetings. European journal of cancer (Oxford, England, 220, 115357.
- Mohyuddin GR,Chakraborty R,Cliff ERS,Derman B (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65,
- Baranda JC, Mohyuddin GR, Bur AM, Shnayder Y, Sweeney KR, Kakarala K, Prouty M, Pathak H, Puri R, Mitra A, Madan R, Forrest ML, Huang A, Weir S, Godwin AK, Alhakamy NA, Griffin JD, Berkland C (2023). A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors. Translational medicine communications, 8,
- Mohyuddin GR, Goodman A (2025). Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials. Nature reviews. Clinical oncology,
- Vaquera-Alfaro HA, Nasrollahi E, Mangala YO, Russler-Germain D, Goodman A, Mohyuddin G (2025). Prevalence of medical writing in hematological malignancy review articles. BMC cancer, 25(1), 720.
- Almasri J, Hasan B, Tarakji Z, Naffa' FW, Warner L, Mian H, Chakraborty R, Mohyuddin GR, Abdel-Rahman Z, Al Hadidi (2025). Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis. Clinical hematology international, 7(4), 1-20.
- Bashy B, Shah D, Steensma D, Van Oekelen O, Chakraborty R, Mohyuddin G (2025). Differences in adverse events between manuscript and drug labels for myeloma T-cell-redirecting therapies. British journal of haematology, 207(4), 1659-1663.
- Mohyuddin GR, Goodman AM, Chakraborty (2025). Contextualizing results of randomized trials in smoldering myeloma. The oncologist, 30(9),
- Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin G (2025). Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. Leukemia, 39(9), 2289-2291.
- Olivier T, Smith C, Prasad V, Mohyuddin G (2025). Oncology "Me-Too" Drugs Compared With Original Drugs in Randomized Clinical Trials. JAMA internal medicine, 185(9), 1159-1162.
- Mehra N, Neupane K, Mohyuddin GR, Plasma Cell Dyscrasias in South Asia Grou (2025). Research landscape of plasma cell disorders in South Asia: a call for collaboration. The Lancet. Haematology, 12(8), e572-e573.
- Mohyuddin GR, Chakraborty R, Berger K, Winborg R, Barnes MS, Hurtado Martinez JA, Hydren JR, Sborov D, Godara A, McClune B, Booth CM, Cliff ER (2025). Patient Preferences on Clinical Decision Making in Multiple Myeloma. JCO oncology practice, OP2500322.
- Chahine Z, Meirson T, Gilboa S, Mohyuddin G (2025). How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes. The oncologist, 30(7),
- Mohyuddin GR, Lemieux M, Chakraborty R, Gertz (2026). Why We Do Not Recommend That People With High-Risk Smoldering Myeloma Receive Treatment. American journal of hematology, 101(3), 409-412.
- Visram A, Seow H, Chakraborty R, Pond G, Gayowsky A, Mohyuddin GR, Hadidi SA, Hansen DK, Sidana S, Gouda R, Garcia-Horton A, Fonseca R, Mian (2026). Second primary malignancy in multiple myeloma: does a prior malignancy matter?. Haematologica,
- Al Hadidi S, Mian H, Chakraborty R, Mohyuddin G (2026). Abstract Factory-Research Culture Harming Medical Education. JAMA, 335(3), 213-214.
- Ludwig H, Kastritis E, Bernhard S, van de Donk NWCJ, Boccadoro M, Terpos E, Musto P, Sonneveld P, Mohyuddin G (2026). Temporal trends in progression risk in smoldering myeloma: a systematic review. EClinicalMedicine, 91, 103750.
- Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R, Mai EK, Chakraborty R, Hadidi SA, Mohan M, Szabo A, Van Oekelen O, Scheffer Cliff ER, Mohyuddin G (2025). Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials. Journal of the National Cancer Institute,
Review
- Ouchveridze E, Berger K, Mohyuddin G (2022). Value in Myeloma Care: Myth or Reality. Current hematologic malignancy reports, 17, 206-216.
- Wayant C, Mohyuddin GR, Prasad (2022). The accelerated approval pathway in oncology: Balancing the benefits and potential harms. Journal of cancer policy, 32, 100323.
- Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy. Critical reviews in oncology/hematology, 166, 103453.
- Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin G (2023). Multiple Myeloma in Young Patients: A Scoping Review. Clinical lymphoma, myeloma & leukemia, 24(1), 15-22.
- Beechinor RJ, Mohyuddin GR, Mitchell DE, Aaron D, Mahmoudjafari (2023). The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue. Journal of cancer policy, 38, 100446.
- Vaquera-Alfaro HA, Gómez-De León A, Desai N, Mehra N, Mohyuddin G (2024). Transplant in myeloma: individualized approaches needed depending on context, access and biology. Bone marrow transplantation,
- Zhukovsky S, White J, Chakraborty R, Costa LJ, Van Oekelen O, Sborov DW, Cliff ERS, Mohyuddin G (2024). Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria. Leukemia & lymphoma, 1-10.
- Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock I (2025). Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. The Lancet. Oncology, 26(2), e80-e89.
- Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin G (2025). The past, present, and future of myeloma staging and risk prognostication. The oncologist, 30(10),
- Shah D, Shah V, Shah K, Shah PJ, Alsadhan M, Haslam A, Prasad V, Qazilbash MH, Chakraborty R, Mohyuddin G (2025). Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies. EClinicalMedicine, 86, 103378.
- Neupane K, Singstock M, Shah D, Dahal R, Mian H, Smith F, Chakraborty R, Al Hadidi S, Mainou M, Grajales-Cruz A, Naqvi SMH, Shain KH, Goodman A, Costa LJ, Qazilbash M, Mohyuddin G (2026). Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review. British journal of haematology,
Case Report
- Yacoub A, Mohyuddin GR, Nazzaro JM (2019). Bilateral subthalmic nucleus deep brain stimulation with microelectrode recordings in the setting of mild inherited hemophilia B: a case report. Int J Neurosci, 129(9), 933-935.
- Mohyuddin GR, Sultan F, Zhang K, Khaleeq G (2013). Sulfasalazine induced lung toxicity masquerading as sarcoidosis--case report and review of the literature. Sarcoidosis Vasc Diffuse Lung Dis, 30(3), 226-30.
- Mohyuddin G, Rabinowitz (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7, 292.
- Mohyuddin GR, Male H (2016). A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection-A Case Report and Review of the Literature. Case reports in hematology, 2016, 4839146.
- Mohyuddin GR, Yacoub (2016). Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature. Case reports in hematology, 2016, 9515404.
- Mohyuddin GR, Sultan F, Khaleeq (2012). A rare presentation of a rare disease: pulmonary lymphomatoid granulomatosis. Case reports in pulmonology, 2012, 371490.
- Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin G (2018). Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus, 10(6), e2805.
- Moosajee SM, Mohyuddin GR, Khan S, Kamal A (2013). Acute acquired demyelinating polyneuropathy–an initial presentation of diffuse large B cell lymphoma. 4(1), 35-8.
Editorial
- Mohyuddin GR, Banerjee R, Goodman A (2021). Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern. European journal of cancer (Oxford, England, 157, 533-535.
- Smith C, Booth CM, Mohyuddin G (2024). Dietary interventions, statistical power, and unanswered questions. Journal of the National Cancer Institute, 116(8), 1404-1405.
Letter
- Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, McClune B (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. [Letter to the editor]. Leuk Lymphoma, 61(10), 2519-2522.
- Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B (2020). Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. [Letter to the editor]. Leuk Lymphoma, 61(11), 2760-2762.
- Mohyuddin GR, Okoniewski M, Diab O, Ganguly S, Shune L, Abdallah AO, McGuirk J, McClune B (2021). Maintenance regimens after a second autologous transplant for multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 62(3), 758-760.
- Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR (2020). Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. [Letter to the editor]. Leuk Lymphoma, 61(5), 1254-1256.
- Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH (2018). A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. [Letter to the editor]. Leuk Lymphoma, 59(2), 515-518.
- Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V (2021). The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. [Letter to the editor]. Leuk Lymphoma, 1-3.
- Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2021). Multiple myeloma triplet therapies: baseline characteristics and control groups. [Letter to the editor]. Lancet, 397(10285), 1620-1621.
- Mohyuddin GR, Roller J, Shune L, Lin T, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh (2019). Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. Hematology/oncology and stem cell therapy, 12(3), 171-173.
- Ripp J, Mohyuddin GR, Al-Jumayli M, Huang (2021). Outcomes in older patients with NSCLC receiving immunotherapy: A single center experience. Journal of geriatric oncology,
- Goodman AM, Mohyuddin GR, Prasad (2022). Ivosidenib and Azacitidine in IDH1-Mutated AML. The New England journal of medicine, 386(26), 2536.
- Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin G (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. British journal of haematology, 197(6), e86-e88.
- Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin G (2022). Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. British journal of haematology, 196(5), 1274-1277.
- Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin G (2022). Post-protocol therapy and informative censoring in the CANDOR study. The Lancet. Oncology, 23(3), e97.
- Mohyuddin GR, Goodman AM, Knopf (2022). Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature. Journal of clinical oncology, 40(1), 105-106.
- Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, Sborov (2022). Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. Blood cancer journal, 12(12), 168.
- Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin G (2022). Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood cancer journal, 12(11), 155.
- Cliff ERS,Mian H,Mohyuddin G (2022). Teclistamab in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine, 387(18), 1721-1722.
- Ouchveridze E,Booth C,Mohyuddin G (2023). Subgroups and precision in myeloma. Journal of cancer policy, 35,
- Mohyuddin GR, Goodman A (2023). Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populations. European journal of cancer (Oxford, England, 185, 164-166.
- Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin G (2023). Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. Journal of clinical oncology, 41(10), 1949-1951.
- Mohyuddin GR, Kapur R, Costa (2023). Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?. British journal of haematology,
- Tariq SM,Abdallah AO,Goodman A,Sborov D,Mohyuddin GR,Britt (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clinical hematology international, 5(2-3), 170-176.
- Bindal P,Najjar M,Koehn K,Godara A,Sborov DW,McClune B,Jullian K,Wagner C,Mohyuddin G (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma,
- Gil K,Abbasi S,Mehta K,McClune B,Sborov D,Ahmed N,Abdallah AO,Ganguly S,McGuirk J,Shune L,Mohyuddin G (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical hematology international, 4(1-2), 56-59.
- Chakraborty R,Hadidi SA,Scheffer Cliff ER,Mohyuddin G (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma?. Blood advances, 7(15), 3932-3935.
- Beechinor RJ, Mahmoudjafari Z, Mohyuddin G (2023). Financial Toxicity in Oncology, More Unanswered Questions. Journal of clinical oncology, JCO2300915.
- Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan (2024). Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood cancer journal, 14(1), 36.
- Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov (2024). Performance of newer myeloma staging systems in a contemporary, large patient cohort. Blood cancer journal, 14(1), 95.
- Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan (2024). Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood cancer journal, 14(1), 137.
- Mellgard G,Gilligan M,Cliff ERS,Bhutani D,Mohyuddin GR,Eisenberger A,Lentzsch S,Chakraborty (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3),
- Mohyuddin GR,Mian H,Gayowsky A,Seow H,Chakraborty R,Pond GR,Al Hadidi S,Visram (2024). Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study. Blood cancer journal, 14(1),
- Visram A,Chan KKW,Seow H,Pond G,Gayowsky A,Mohyuddin GR,McCurdy A,Sandhu I,Venner C,Lancman G,Balitsky A,Kouroukis T,Bruins R,Kumar S,Fonseca R,Mian (2025). Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study. Haematologica, 110(1), 228-233.
- Chunara F, Lugo C, Osinski K, Shah MR, Shah N, Kent J, Mohyuddin GR, Radhakrishnan SV, Kaur G, Chakraborty R, Banerjee R, Rasche L, Schinke C, D'Souza A, Szabo A, Mohan (2025). Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients. Blood cancer journal, 15(1), 61.
An amazing, caring Doctor, positive in every way. Thankful for him and Bree for being there with all my questions and concerns. Also, thanks to their entire staff for being so kind, helpful and caring?
Dr. Mohy is very professional in explaining your situation and listens to your concerns.
You don't get any better then Dr Mohy Ud Din! He listens and cares very much for his patients. What I love the most is that he cares about my quality of life. He is always looking to improve my health even when I am not. He truly is the best!
Very caring, listened to my concerns.
Dr, Ghulam Rehman Rehman Mohy Ud Din, has become one of my endearing, reliable, and trustworthy fountain of information for me. He explains everything in such a way that I feel like I am his only patient, and he cares for me exclusively. I truly appreciate him and his knowledge.
He is absolutely the best.
Extremely intelligent and caring, saved my life.
He listens and answers your questions'very knowledgeable
I consider myself blessed to have Dr. Manni as my doctor. He's kind, compassionate, very knowledgeable and a great listener. I leave knowing exactly how I'm doing, what he's watching for and what's next, treatment-wise. I trust him completely .
Dr Manni is very courteous and listens well to answer all of my questions and concerns. I appreciate him and the staff for the level of care they provide.
He is the pinnacle of professional medical care. A gentleman who avails incredible medical to me and has made my cancer and the associated pain tolerable.
Great doctor
He is such an excellent Dr. I believe he's saved my life.
Very professional and knowledgeable and keeps you informed about your treatment .
He is very caring for his patients and wants the best care for them
I felt like I was in good hands and I could trust the Dr. to care for me.
Dr. Mohy is a professional in the study and treatment of my homotopical malignancies and is quick to address your concerns. I'd rate him as a 10-stars recipient.
A nice caring Dr. for the patients preferences.
Interacting with him is always a pleasant experience. He makes being a cancer patient much easier to deal with. Not just a professional, but a really nice guy.
Very good doctor I recommend him [TRANSLATED]
He is the top of the line when it comes to cancer care. The best thing we did for my husband was switch to Huntsman and Dr Moody Ud Din. My husband is in remission now.
Just a great physician who knows his craft and treats patients very respectfully.
Dr Manni is the best doctor I have had the pleasure to be treated. He is thoughtful, kind, knowledgeable, I can't say enough good about him and I know that my cancer journey is so much more tolerable because he is my doctor. Thank you Dr Manni
Seemed very nice I I feel comfortable being under his care
It was nice to talk to the Doctor and the staff. Steve the coordinator was very helpful
the best doctor, ever!
He is very understanding and goes over everything and makes sure you understand what he is telling you
Nothing but high priases for Dr. Mohy Ud Din!
Doctor Mohy is one of the best, if not the best doctor I have ever had. His knowledge of Multiple Myeloma is off the charts and I feel he really hears me and cares.
Makes you feel like he is on your side .(
Humble, kind, caring. Explained test results thoroughly. Answered all my questions so I could understand. Explained he would be in touch with my other doctors. Discussed follow up and asked if I was comfortable with that.
Dr. Ud Din is very knowledgeable and explained everything in a way that I understood. He was happy with my results as they were far better than when we first met 1 1/2 years ago.
Dr. Mohy Ud Din is as " good as it gets!". He is incredibly polite, extremely knowledgeable and very easy to communicate with. He treats me with the greatest amount of respect I have ever experienced in all of my encounters with medical professionals.
Simply the best
Dr is very concerning about a persons feelings and if needed can find a different way to help
one word - AMAZING
He listened to me and makes sure I am in clued in the decisions
While under the care of Dr Mohy Ud Din I have been stable and had a good life.
I canÕt say enough good things about my Doctor. You and I are so blessed to have him. He takes time with me and makes sure I get all the info about what needs to be done then supports my choices. So grateful.
I really like Dr. MOHY, Treats me like a friend
Caring, explained everything in detail and in a way that I understand. Very knowledgeable.
Dr. Mohy Ud Din displays an incredible combination of professional skill and human compassion that goes beyond bed-size manner.
I am here today because of Dr Mohy Ud Din. What a wonderful doctor with a gentle touch. If something doesn't work he has a new plan. If I am struggling with side effects, he wants better for me and makes changes. He truly cares about my quality of life and it shows in how he treats me. He really is a caring and wonderful doctor.
When you are diagnosed with a frightening disease, get an expert like Dr Moy uh Din on your team.
Very kind and very smart what else do you need from a doctor
A good Dr who will work with his patients and really cares. Thank you so much!
The most amazing doctor I have ever had. Best bedside manner, treats you like a brother or sister. Not a shred of ego, not presumptuous. Great human. You can tell he is in it to truly give you life.
He is the best!! So caring and always explains every aspect of care and treatment.
Dr Mohy Ud Din is the best. His heart felt concern and intelligent positivity were wonderful during a very scary time. He went about and beyond to call and talk to me himself. When my appointment with him was automatically cancelled while I was inpatient at the University Hospital, he walked over from Huntsman and met with me in my hospital room anyway. Facing cancer, knowing you have the best Doctor in the world is a great comfort! Thank you Dr Mohy Ud Din
This Dr. studies his patients information & explains what's best for them including them in a plan of action for a healthy lifestyle.
Dr. Mohy Ud Din is very knowledgeable, and very caring. I always enjoy my visits with him. Makes you feel he has all the time in the world to answer your questions.
IÕve had many oncologists since my diagnosis ten years ago. So I know when IÕm being treated with respect care and being listened too. Dr Mani is the best oncologist IÕve had. I highly recommend him and his staff.
Such an amazing doctor, so caring!!
very knowledgeable and caring
He is very kind
Dr. Mohy Ud Din is a thoughtful, careful, patient, understanding, knowledgeable doctor! He took time out of his busy day to personally call me when test results came back that he knew I would be worried about so that I could have a peaceful weekend! Dr. Mohy Ud Din is everything you would want in a doctor!! 10 out of 10!! I feel very confident under his care!
Dr Mohy Ud Din aka Dr Manni is the physician you want when diagnosed with Multiple Myeloma. Not only is he an exceptional Oncologist/Hematologist but he also is a very caring person.
Super caring and pleasant to work with. Outstanding doctor in care and knowledge
He was very nice and explained everything in a way that I felt confident in his decisions and am glad he is my doctor.
I have total confidence and trust in Dr. Manni. I feel very lucky to have him as my doctor.
The doctor is consistently calming during my treatment for a painful, and potentially fatal disease. My wife accompanies me to aid in my movement about the facility. She speaks volumes regarding the doctors interactions with us. VERY PROFESSIONAL -Very easy to converse with re: my treatment.
Very good doctor
The Best??
Intelligent caring professional
I have complete trust in Dr. Mohy Ud Din. He is professional, explains things very clearly, and involves me in decision making about my treatment. He's kind and personable as well. I'm so glad I chose Huntsman for my care.
Dr Mohy is an awesome Doctor. Very knowledgeable and has a great bedside manner. Listens and answers questions. He also asks questions to better know where you are in treatment.
Doctor moly Ud Din is excellent in every way and his empathy and desire to help his patients caused him to schedule me for tests and diagnosis in one week (emergency measures). to prevent Further deterioration of my body
He is Awesome
He is open, honest with good advice on my health needs.
Excelente doctor se preocupa de que yo entienda todo lo que me dice . Muy buen doctor
Excellent Professional.
He does a very professional job.
Dr Mohy Ud Din is a caring individual who, while remaining professional, shows great kindness and understanding.
Dr Mohy Ud Din messaged me as soon as the tests were in so I didn't have to worry about it for days before the appointment.
Dr. Manni is caring and kind. He has put together an excellent treatment plan for me.
I feel lucky to have been assigned to Dr UdDin. He is bright, articulate, kind, respectful and clearly so very competent. He is just a lovely human and the kind of doctor everyone should be so lucky to have provide care. I trust him completely and am grateful for his wonderful care.
I feel like he really has my best interest at heart. He is my friend and is fun although always professional. He is always prepared to discuss my case with detailed information.
Dr Mohy is a very caring, concerned Dr. towards his patients.would highly recommend him and Huntsman to anyone needing treatment.
Dr. Mohy Ud Din is a physician with a caring approach that develops an intervention plan that is understandable to the patient.
Both were very good at looking for the real issues with my heath. I know I'm in good hands not just a number. Thank you!
One of the best doctors I have ever had. Has a good manner about him listen carefully , makes good informed decisions based on my needs.
I feel well cared for and listened to
Very very knowledgeable, and competent explained everything on my level. OUTSTANDING.
The doctor is always very kind and very professional. He conveys a sense of understanding of my needs and the best medical practices to apply to those knees. I enjoy my visits with the doctor.
Appreciate working with him, he is kind, and a good listner
I love Dr. Manny. He seems genuinely concerned for me and my health and is trying to help me as best he can.
Simply amazing doctor!!!
Kind and compassionate.
Excellent physician, very knowledgeable and courteous.
He has been great to work with us.
I would 100% recommend this Dr to others. He is an excellent doctor with a straight forward manner of speaking to you. He is also very compassionate.
This man is what a doctor is supposed to be. Caring. Slow and precise. Thoughtful. Concerned. He and his team are the most special people you will ever meet. While you embark on you journey, they are so great at assuaging your anxieties and getting you in a positive, healing mindset. I am so grateful to be blessed to have this team in my fight.
I couldn't be more grateful to have him as my Doctor!
Very good team and easy to talk to and understand!
He always listens to me and explains things very well. He is the best.
I really appreciate the way the whole staff works together to take care of me
If you want a provider you can trust and give you a good quantity of life and someone who will listen and and act on things he promises you. Go see Dr Mohy Ud Din. I promise, you will walk away happier and healthier then before. He is a 10/10 doctor and so amazing!
He is so KIND & CARING !!!!!!!!!! He gives me PEACE & COMFORT !!!!!!!!!! He takes such good care of me !!!!! He talks about my blood work & answers all my questions !!!!!
He is very relatable and funny he is in the end skilled with a broad base of knowledge but is not arrogant. He has been very helpful in improving my outlook for the future
Dr. Mohy Ud Din is the consummate health care provider. He is knowledgeable, accessible and very patient-centered. Without question, the best physician I have ever been associated with in my life.
Dr. Mohy Ud Din is exceptional as a researcher and doctor. He is not only knowledgeable about my cancer, but he is able to explain it in terms I can understand.
He is an exceptional Dr. with a rare combination of current knowledge, with a kind, caring sincerity.
He is very caring and appreciates my opinion
He spoke to us in away we understood everything he said and when he spoke in medical terms he immediately defined them in plain English .
He spent a lot of time with me and I put great trust in his knowledge.
Excellent oncologist. Very pleased with his approach to treatment and the quality of care.
If one has Multiple Myeloma...I strongly encourage them to have Dr Ghulam Rehman Mohy Ud Din aka: Dr Manni as their Oncologist/Hematologist. He is a very knowledgeable and caring physician and I feel very privileged to have him as my physician.
I feel very blessed that he is very confident with the treatment he has in store for me. I feel he is very knowledgeable,and professional, that he has a good heart and genuinely cares for me.
Dr Mohy Ud Din is kind, knowledgeable, and professional. I am always pleased with the care I receive from the myeloma team .
Best Dr bar none. Very open, honest, caring and very knowledgeable.
I have great confidence in Dr. Mohy Ud Din. He has proven time and time again he is for the patient and the care they receive. I am grateful for his care and the team he leads.
Dr. Ud Din explained my symptoms and my care going forward in a way that I understood. He listened to my concerns and was forthright in letting me know my diagnosis.
Very personable but also very knowledgeable and that is a great combination.
I'm grateful that Dr. Mohy Ud Din is the doctor directing my multiple myeloma care. He is so knowledgeable, kind and understanding. He is a good listener and takes the time to answer all of my questions. He looks at me as a person, not just another patient.
My wife and I came away from our initial (and only, so far) consultation very impressed, and happy that he will be the primary physician in my CAR-T journey.
The doctor and his staff are excellent !
Great doctor. Very happy with his care
I trust him completely with my care.
Great doctor and individual.
He is very kind and caring, and I trust his professional apinion.
He inspired my confidence very quickly. He communicated very effectively. He has a wonderful manner and I am especially grateful for his patience in discussing my questions
He is a truly caring man, taking as much time as you need so that you understand everything and he will take time to answer any question you have.
Dr. Mohy Ud Din is a consummate professional. He is very knowledgeable and has a pleasant demeanor. He listens to my questions and gives me honest, well-researched responses. I always come away from our appointments feeling grateful to be in the care of such an expert and kind doctor.
Dr. Mohy Ud Din is a very knowledgeable oncologist who is patient centered, professional and accessible. Dr. Mohy Ud Din is very effective communicator who carefully listens and responds to patient needs. ¿-an outstanding physician
Dr Mohy Ud Dim is the kind of physician everyone would be thrilled to have when facing a frightening diagnosis. He is one in a million!
He explained everything about stem cell transplants in a way I could understand, and gave me his straight forward answer as to whether he thought it would help me or not.
Dr. Din was very attentive and serious about his evaluation of my current condition. Dr. Din receives ***** in my opinion.
Dr Manny is a great listener and always has a plan.
He so wonderful. So caring and so knowledgeable. I know he will drop everything to make sure I'm ok because he has before.
Dr. Manni is kind and caring, and an expert in multiple myeloma treatment. I feel very well cared for by him and his team.
He has been one of the best doctors I have encountered ! He has empathy and the ability to understand what I must be going thru as a patient.
He is the best Dr. I have had for my Multiple Myeloma treatment in the last 8 years,
Explained what he saw very well.
spent time with me!!!! explained things, quized me to see if I understood. Very knowledgeable on treatments and personal conditions
One of the best doctors. Listens to what I need and follow through promptly.
Dr. Mani truly cares about my health and what is going on. He never hesitated to not know what to do and always has a backup plan ready to go.
He was very caring and personable. I trust he knows his expertise Generally liked him
The best!
Feel blessed to have this doctor. Sincere, great bedside manner, does not speak down to you, provides options and allows you to choose paths based on presenting data. Fantastic doctor with whom I look forward to working. He has a great team, as well.
My first visit with him was exceptional in every way. I trust him implicitly with my care.
Was awesome!!
Excellent care. Very clear in his explanation. Very caring.
Dr Mohy-Ud-Din is a very good practitioner and is very attentive and shows he cares by the way he interacts. I think he is a very skilled doctor.
Dr Mohy-Ud-Din happened to have a fellow with him that day and he introduced him and explained why he was there and if I had any question. I wanted to tell the new doctor what an amazing opportunity this was for him because you couldnt find a better doctor to learn from and I imagine this is why he was shadowing Dr Mohy-Ud-Din. Dr Manny is amazing! Always takes time to explain things and why we are doing them. Allows me time to ask as many questions as I want without feeling pressured which is rare in todays appointments always being rushed. I always feel comfortable at my appointments and walk away feeling reassured that I am in the best hands possible and will have a positive outcome.
Very professional and easy to talk to
Very positive
I felt his compassion and consideration towards me as a Multiple Myeloma patient and the future of my well being. I respected his knowledge, kindness and honesty towards me and my families future dealing with Multiple Myeloma. His experience dealing with cancer patients like me gave me a positive feeling.
I have had excellent care from Dr Mohy ud Din. He listens and explains things in detail. He comes across as compassionate and very enthusiastic. I felt like I had his support 100%.
I would highly recommend this Greg young Dr!
Dr Mohy-ud-din explained everything very well. He explained possible treatments, and recommended the one he thought would be most beneficial at this time.
Takes the time is thorough very caring
Dr. Mohy-Ud-Din was very well prepared for my appointment. He said he would take all the time necessary for me to understand and to answer all my questions. He is kind and very personable.
Continues to be polite, personal, and patiently addressing my questions and concerns.
He is so clear when he is explaining the symptoms and treatments. He gives me choices, and explains what to expect with each decision. And he is so cheerful and fun to see. He makes dealing with cancer just a little bit easier.
Dr Mohyuddin is incredible doctor. I trust his wisdom and expertise when it comes to my myeloma care. He and his wonderful team have given me great insight and ongoing help through each step of my journey.
He is open minded and willing to monitor my care without pushing medications on me.
Dr Mohy Ud Din is wonderful! He always includes me in all decisions, asks for my opinion, explains things on a level that I understand and always makes time for me. I feel like Im talking to a close friend when I meet with him and when we are literally talking about life saving decisions. I really admire him and I am so thankful I have him to care for me.
Dr. Mohy Ud Din is a consummate professional. I have been very impressed with his thorough and thoughtful approach to myeloma and precursor conditions. As a high-risk smoldering myeloma patient, I feel very grateful to have care provided by an expert in the field who is a specialist and conducts research in this exact disease. I ask loads of questions and read dozens of study summaries, attend on-line seminars, etc. Dr. Manni has been able to respond to all of my questions in a thought and well-reasoned manner. He has read every study I have asked about and is able to compare and contrast the varied recommendations for treatment. I cannot say enough good about him and his team and, again, feel very grateful to be a patient in their exceptional care.
Dr Mohy-Ud-Din is an amazing physician. He is so kind and knowledgeable, compassionate, reassuring, and clearly knowledgeable. I am so pleased that he is my doctor!
He was charming and explained everything very well. He answered all men questions in great detail which is exactly what I wanted. He carefully explained possible treatments for my future care. I came for a 2nd opinion and now I would definitely like Dr Mohy-Ud-Din to be my Oncologist.
He was very personal. professional and polite. He listened, explained in detail about my visit conditions and plan of care. He took time to address my concerns and questions to my understanding along with my family. He personally called to explain the results of my tests, and labs along with the plan of care. He took time to be sure I understood what the results were and meant. Then he detailed my plan of care. He also considered my input and questions. He didn't rush our visit. I along with my family felt we really matter. He personalized my visit to me and my needs. I wish more Providers had this attribute. I wasn't just a number. Thank you for providing such a positive experience. Sincerely, [NAME REMOVED]
Dr Mohs-Ud-Din is n to only an Dr Mohs-Ud-Din is not only a very competent Oncologist/Hematologist, he takes the time to answer my questions with care & concern & delivers his answers in non medical terminology that I can easily understand.
He spent time with me to explain my illness and the follow up procedures that I will need.
Very positive and encouraging, even though some results are troubling. Has a very good way of explaining things clearly in a way that I can understand.
Dr. Mohy-Un-Din is very courteous and takes extreme efforts to understand my needs. Very professional and knowledgeable.
Great "bedside manor". Very personable and knowledgeable.
Extremely competent and can communicate effectively with patients. He is personable and cares about his patients
Dr. Ghulam Rehman Mohy-Ud-Din is a highly professional, knowledgeable, personable, and accessible oncologist. Excellent, caring physician.
Not only was I confident in his care, he drew me into the conversation and explained what I needed to know very well. Ie is so knowledgeable and so easy to talk to. He was gracious enough to include a family member by phone during our conversation and made sure we all understood the diagnosis and what to expect. He truly is an amazing physician!
I welcome any conversations with Dr. Mohy-Ud-Din. He was attentive to my concerns, extremely clear in his explanations, and evidenced care and optimism in relating to me and my husband.
He listens intently, and I believe he may have saved my life.
The best!
Exhalant very. Nice
Even though his diagnosis didnt identify immediate problems, he made me feel good about additional testing to rule out some possibilities.
See earlier comments. He sets the bar for professionalism, knowledge, politeness and respect. He is a tremendous asset to the U of U and to Huntsman Cancer Institute in particular.
Very nice and seemed very intelligent.
He was very respectful of my treatment wishes.
Dr. Mohyuddin is kind and patient. He does an excellent job of explaining my disease and the treatment options and process to me. He makes sure I understand. I feel calm and confident about my treatment with him.
Dr mohy-Uh-Din is cheerful, kind and responsive to my needs. I think I'm still here on earth because of his quick action.
Dr.Manny is the best all around.
Dr Manni has been the most wonderful doctor I can imagine. I get my treatments in St George but he is the one that decides what treatments are needed. Because of him I am now in remission. I feel like he really cares about me.
Very concerned and trying hard to get all the appointments I need to find out what is going on with me.
Absolutely my kind of Doctor! He talks to you so you TOTALLY understand your condition.
Intelligent and compassionate
He is an amzaimhg doctor
He is an amazing Dr. I have 2 rare diseases and he has done so much to figure out treatment.
Dr Mohy Ud din is a wonderful, caring physician. I enjoy talking to him, He is extremely patient and answers all my questions
My doctor, transplant coordinator, and social worker have been great. They have made a great positive impact on negotiating this very stressful illness.
Good
Dr Manni and his team are amazing. I always leave with all questions answered.
He was kind and listened as he presented.
Pleasant to talk to. Very understanding, and informed, always answered every question with care and compassion
Dr was very informative and clear in explaining her self.
Doctor was excellent. Extremely conscientious. This was my first visit, and he had obviously gone through my previous records very carefully. Excellent listener. Good at explaining. Just overall great.
Dr. Mushy-Ud-Din was fantastic. Talk about terrific bed-side manner. He showed terrific compassion, exhibited tremendous expertise, and was dedicated to educating me as a patient. Rarely if ever have I had such a positive interaction with a doctor.
Dr M. Mohyuddin was awesome and spent a lot of time with me
Doctor always explains things in detail and asks if I have any questions. I always leave my appointment fulfilled.
I was very reassured and comfortable with with the whole experience.
I don't do recommendations. But if asked, I will definitely tell them about my team.
Very meaningful discussions and interchange.
The doctor is very knowledgeable and compassionate.
I don't usually recommend anything to friends. I figure they already have someone they're happy with - if they ask I will certainly recommend your services.
The doctor and RN were fantastic!!
Doctor listens and praises you for your questions which encourages you to ask more questions without making you feel dumb. You feel as if you are sitting with a friend and not a medical provider.
The doctor is very good. I trust him because he explains everything to me.
I received a detailed explanation from Dr. Muh Din very clear and to "my level"and "in English" not medical vocabulary. He repeated the explanations until he was sure I understood very clear what he was saying. I love him. :)
Doctor was very concerned that I understand what was going on and constantly asked if I had questions. He is a very concerned doctor and I felt comfortable asking questions and his ability to answer them. I did not feel rushed and he took his time with me.